Russian Scientists Discover Casuarictin in Sea Buckthorn

Russian researchers have identified a new biologically active compound in sea buckthorn leaves — casuarictin, which exhibits a pronounced antitumor effect. Laboratory studies have demonstrated that this natural component can inhibit the growth of cancer cells, making it a potential candidate for developing drugs against oncological diseases. The discovery was made at Russian scientific centers in 2026 and has attracted significant attention from the research community due to its promising medical applications.

Origin and Composition of Casuarictin

Casuarictin is a flavonoid compound found in the leaves of sea buckthorn, a plant widely distributed across Russia and the CIS countries. Sea buckthorn is well-known for its richness in biologically active substances, including vitamins, carotenoids, and antioxidants, which have long been used in folk and scientific medicine. Research into the composition of sea buckthorn leaves, conducted in 2026 by scientists from the Biochemistry Institute of the Russian Academy of Sciences, identified casuarictin as a new element with unique properties.

Sea buckthorn is harvested in spring and summer, with its leaves containing up to 2% flavonoids by dry weight, of which casuarictin comprises a significant portion. Pure casuarictin is isolated using modern extraction and chromatography methods, allowing for yields of up to 150 milligrams per kilogram of dry leaves. These figures are important for scaling up production and further testing of the compound.

Antitumor Properties and Laboratory Testing

In 2026, Russian scientists conducted a series of laboratory studies demonstrating that casuarictin suppresses the growth and proliferation of various tumor cell types, including breast and lung cancer cell lines. Experiments with cell cultures showed that at concentrations ranging from 10 to 50 micromoles, casuarictin reduced cancer cell viability by 40–70% over 72 hours.

These results were obtained at the Petrov Oncology Institute in St. Petersburg, where new anticancer drugs are being developed. The inhibitory effect is enhanced when casuarictin is combined with other biologically active components of sea buckthorn, which may form the basis of a comprehensive therapy with minimal side effects.

Potential for Pharmaceutical Development

The discovery of casuarictin as a powerful tumor cell inhibitor has laid the groundwork for the development of new medications based on it. In 2026, several Russian pharmaceutical companies, including PharmBioTech from Moscow, expressed interest in funding clinical trials and creating extracts with high casuarictin content.

Experts estimate that the costs for developing and conducting clinical trials of a new drug could range from 300 to 500 million rubles, with market launch expected within 5–7 years. This timeframe is due to the necessity of strict safety and efficacy controls, as well as registration with Russian and Eurasian Economic Union health authorities.

Significance for Russian Agriculture and Economy

Sea buckthorn is traditionally cultivated in Siberia and the Russian Far East, where plantations cover thousands of hectares. The newfound demand for the plant’s leaves as raw material for the pharmaceutical industry may stimulate the agricultural sector in these regions. In 2026, the total area of sea buckthorn plantations in Russia exceeds 15,000 hectares, providing a solid base for large-scale leaf harvesting.

Experts from the Russian Ministry of Agriculture note that the development of a bioproduct industry based on sea buckthorn could increase regional incomes by more than 1 billion rubles annually. Furthermore, new leaf processing technologies will create additional jobs and enhance the export potential of Russian phytopharmaceuticals.

Prospects and Next Steps in Research

The next phase of scientific work will involve preclinical studies on animal models and developing methods to stabilize casuarictin in pharmaceutical formulations. In 2026, research teams plan to begin trials on laboratory mice to assess toxicity and efficacy against various tumor types.

Simultaneously, efforts are underway to find synthetic analogs of casuarictin that may possess improved pharmacological properties. These projects are conducted in collaboration with universities in Moscow and Novosibirsk, expanding the research base and increasing the likelihood of developing competitive drugs.

Conclusion: The discovery of casuarictin in sea buckthorn leaves opens new prospects in cancer treatment and stimulates growth in Russia’s pharmaceutical and agricultural sectors.